Vesta Real Estate's 15min chart shows RSI Oversold and Bullish Marubozu pattern.
ByAinvest
Tuesday, Sep 2, 2025 10:02 am ET1min read
ONC--
The growth was largely attributed to the sales of self-developed products, Brukinsa (zanubrutinib capsules) and Tislelizumab (antibody), as well as products licensed from Amgen. Zanubrutinib, in particular, performed exceptionally well, securing the top position in both the U.S. and global BTK inhibitor markets. Global sales of zanubrutinib reached 12.527 billion yuan in the first half of 2025, with a year-on-year increase of 56.2%. In the U.S. market, sales amounted to 8.958 billion yuan, growing 51.7% year-on-year [1].
The strong performance of BeiGene's stock comes amidst broader market conditions. According to Vesta Real Estate, the Relative Strength Index (RSI) has reached oversold levels, and a bullish Marubozu candle was observed at 09:00 on February 2, 2025. These indicators suggest that the stock price has declined rapidly and fallen below its fundamental support level, leading to a potential continuation of bullish momentum [2].
References:
[1] https://news.futunn.com/post/61555960/us-stock-market-update-beigene-oncus-surges-over-9-with
[2] https://vesta-real-estate.com/15-minute-chart
VTMX--
Based on the 15-minute chart provided by Vesta Real Estate, the Relative Strength Index (RSI) has reached oversold levels. Furthermore, the stock has exhibited a bullish Marubozu candle at 09:00 on February 2, 2025. This indicates that the stock price has declined rapidly and fallen below its fundamental support level. Consequently, buyers have taken control of the market, and a continuation of bullish momentum is likely.
On Tuesday, BeiGene (ONC.US) surged over 9%, closing at $334.20. According to Zhitong Finance, the stock's performance was driven by robust financial results in the first half of 2025. BeiGene reported total revenue of 17.518 billion yuan, a 46.03% year-on-year increase, with product revenue reaching 17.36 billion yuan, up 45.8%. The company also recorded a net profit of 450 million yuan, marking its first profit since the beginning of the year [1].The growth was largely attributed to the sales of self-developed products, Brukinsa (zanubrutinib capsules) and Tislelizumab (antibody), as well as products licensed from Amgen. Zanubrutinib, in particular, performed exceptionally well, securing the top position in both the U.S. and global BTK inhibitor markets. Global sales of zanubrutinib reached 12.527 billion yuan in the first half of 2025, with a year-on-year increase of 56.2%. In the U.S. market, sales amounted to 8.958 billion yuan, growing 51.7% year-on-year [1].
The strong performance of BeiGene's stock comes amidst broader market conditions. According to Vesta Real Estate, the Relative Strength Index (RSI) has reached oversold levels, and a bullish Marubozu candle was observed at 09:00 on February 2, 2025. These indicators suggest that the stock price has declined rapidly and fallen below its fundamental support level, leading to a potential continuation of bullish momentum [2].
References:
[1] https://news.futunn.com/post/61555960/us-stock-market-update-beigene-oncus-surges-over-9-with
[2] https://vesta-real-estate.com/15-minute-chart
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet